drugset / Trial / NCT00071422
Safety and Efficacy of INGAP-Peptide in Patients With Type 2 Diabetes
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Insulin is a chemical that the body needs in order to use or store sugar. It is made by a type of cell called a beta cell which resides in an organ known as the pancreas. Type 2 diabetes is a disease where the beta cells are unable to meet a person's insulin needs. Sugar levels rise in the blood as a result. INGAP-Peptide is being tested to attempt to create new beta cells in the pancreas, and to improve the ability to produce insulin in type 2 diabetic patients.
Timeline
- Start
- 2003-10
- Primary completion
- 2004-06
- Completion
- 2004-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INGAP Peptide | Peptide | 300 mg | Subcutaneous |
| Subject | INGAP Peptide | Peptide | 600 mg | Subcutaneous |